Drug · CHEMBL185
FLUOROURACIL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. FLUOROURACIL. Drugs and targets, record CHEMBL185. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL185
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- 5.f.u., Accusite, Actikerall, Adrucil, Carac, Efudex, Efudix, Fluoro-uracil roche, Fluoroplex, Fluorouracil component of folfox, Tolak
- ChEMBL
- Other names
- 5 FU, 5-FU, 5-fluorouracil, 5-fluoruracil, Fluorouracilo, Fluorouracilum, Fluorouricil, Fluracil, NSC-19893, Phthoruracil, Queroplex, RO 2-9757, RO-2-9757, RO-29757
- ChEMBL
- Open Targets' highest stage
- Approval, for 11 of its 190 diseases, from ATC, ClinicalTrials.gov, DailyMed, PMDA and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| TYMS | Thymidylate synthase | Thymidylate synthase inhibitor | INHIBITOR | https://conductscience.org/library/genes/7298 |
Source ChEMBL
Diseases190
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| colorectal cancer | Phase 3 | ClinicalTrials.gov | 597 | 596 | https://conductscience.org/library/drugs?q=MONDO_0005575 |
| gastric cancer | Phase 3 | ClinicalTrials.gov | 166 | 166 | https://conductscience.org/library/drugs?q=MONDO_0001056 |
| rectal cancer | Phase 3 | ClinicalTrials.gov | 162 | 162 | https://conductscience.org/library/drugs?q=MONDO_0006519 |
| malignant pancreatic neoplasm | Approval | ClinicalTrials.gov | 148 | 148 | https://conductscience.org/library/drugs?q=MONDO_0009831 |
| pancreatic neoplasm | Approval | ClinicalTrials.gov | 146 | 146 | https://conductscience.org/library/drugs?q=MONDO_0021040 |
| breast cancer | Phase 3 | ClinicalTrials.gov | 134 | 134 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| pancreatic adenocarcinoma | Phase 3 | ClinicalTrials.gov | 127 | 127 | https://conductscience.org/library/drugs?q=MONDO_0006047 |
| gastric adenocarcinoma | Phase 3 | ClinicalTrials.gov | 120 | 120 | https://conductscience.org/library/drugs?q=MONDO_0005036 |
| gastroesophageal junction adenocarcinoma | Phase 3 | ClinicalTrials.gov | 106 | 106 | https://conductscience.org/library/drugs?q=MONDO_0003219 |
| hepatocellular carcinoma | Approval | ClinicalTrials.gov | 88 | 88 | https://conductscience.org/library/drugs?q=MONDO_0007256 |
1 to 10 of 190Source Open Targets
See all 190 diseasesTrials2,360
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 64 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 287 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01358877 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | Phase 3 | 4,804 | 2018-01-05 | 5-fluorouracil | Its name | ClinicalTrials.gov |
| NCT02135419 | Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions | Phase 3 | 4,446 | 2022-12-02 | fluorouracil | Its name | ClinicalTrials.gov |
| NCT00112918 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer | Phase 3 | 3,451 | 2012-09-06 | fluorouracil | Its name | ClinicalTrials.gov |
| NCT00079274 | Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer | Phase 3 | 3,397 | 2015-02-09 | fluorouracil | Its name | ClinicalTrials.gov |
| NCT00087178 | Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer | Phase 3 | 2,722 | 2022-08-11 | fluorouracil | Its name | ClinicalTrials.gov |
| NCT00096278 | Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer | Phase 3 | 2,710 | 2012-12-03 | fluorouracil | Its name | ClinicalTrials.gov |
| NCT01150045 | Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery | Phase 3 | 2,527 | 2021-08-06 | fluorouracil | Its name | ClinicalTrials.gov |
| NCT00217737 | Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | Phase 3 | 2,431 | 2025-07-20 | fluorouracil | Its name | ClinicalTrials.gov |
| NCT00265850 | Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | Phase 3 | 2,334 | 2017-04-26 | fluorouracil | Its name | ClinicalTrials.gov |
| NCT00014222 | Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer | Phase 3 | 2,104 | 2020-03-10 | fluorouracil | Its name | ClinicalTrials.gov |
1 to 10 of 2,360
See all 2,360 trialsComparisons in its trials378
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause | 205 of 2,400 | 247 of 2,404 | 4,804 | NCT01358877 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: serious adverse events | 792 of 2,364 | 686 of 2,405 | 4,769 | NCT01358877 | Trial comparisons |
| Arm I (Treatment) vs Arm II (Active Monitoring) (Closed Since SEP2021): Incidence of Adverse Events for Each Treatment | 416 of 2,227 | 429 of 2,219 | 4,446 | NCT02135419 | Trial comparisons |
| Arm I (Treatment) vs Arm II (Active Monitoring) (Closed Since SEP2021): deaths from any cause | 55 of 2,227 | 48 of 2,219 | 4,446 | NCT02135419 | Trial comparisons |
| Arm I (Treatment) vs Arm II (Active Monitoring) (Closed Since SEP2021): serious adverse events | 370 of 2,227 | 375 of 2,219 | 4,446 | NCT02135419 | Trial comparisons |
| Adriamycin + Cyclophosphamide vs Fluorouracil + Epirubicin + Cyclophosphamide: serious adverse events | 12 of 1,351 | 26 of 1,337 | 2,688 | NCT00087178 | Trial comparisons |
| Oxaliplatin + Leucovorin + 5-Fluorouracil vs Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab: serious adverse events | 81 of 1,326 | 270 of 1,334 | 2,660 | NCT00096278 | Trial comparisons |
| Capecitabine vs 5-Fluorouracil + Leucovorin: Relapse-Free Survival | 677 of 1,004 | 621 of 983 | 1,987 | NCT00009737 | Trial comparisons |
| Capecitabine vs 5-Fluorouracil + Leucovorin: Disease-free Survival | 656 of 1,004 | 603 of 983 | 1,987 | NCT00009737 | Trial comparisons |
| Capecitabine vs 5-Fluorouracil + Leucovorin: Overall Survival | 804 of 1,004 | 756 of 983 | 1,987 | NCT00009737 | Trial comparisons |
1 to 10 of 378
See all 378 comparisons in its trialsPapers from its trials1,540
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL185
GET https://conductscience.org/api/drugs/v1/CHEMBL185/diseases?page=2